FDA Approval Targets Rare Kidney Disease - Poll - MDSpire

FDA Approval Targets Rare Kidney Disease

Phase 3 data showed greater proteinuria reduction vs irbesartan, with similar tolerability and a 1.1 mL/min/1.73 m² difference in estimated glomerular filtration rate at 108 weeks.

  • By

  • Kathryn Wighton

  • April 14, 2026

  • 2 min

Share

Original Source(s)

FDA Approval Targets Rare Kidney Disease

  • by Kathryn Wighton

  • April 14, 2026

Related Content

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.

New Label Expansion in Generalized Myasthenia Gravis

Phase 3 ADAPT SERON data supported efgartigimod use across antibody subtypes often underrepresented in trials.

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.